Overview

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Status:
Completed

Trial end date:
2013-10-01

Target enrollment:

Participant gender:

Summary

This is a single institution, open label, phase II study in androgen-independent prostate cancer patients who are chemotherapy-naïve. Patients will receive Torisel® 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion.

Phase:

Phase 2

Details

Lead Sponsor:

Oncology Specialists, S.C.

Collaborator:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Everolimus
Sirolimus